MONTREAL, March 22,
2022 /CNW/ - Lumiera Health
Inc. (TSXV: NHP) (the "Company" or
"Lumiera "), a company specializing in the development
and commercialization of natural health products, is pleased to
provide an update to announce that the corporate strategy and plans
that were put place in 2021, are continuing to prove successful
with Lumiera's fiscal Q1'22 being another strong quarter with sales
+25% vs Q1 2021.
The increase in the Company's sales has been driven by the new
sales and in-store training team deployed late last year. The
team is helping build distribution and training key in-store
influencers on the benefits of Lumiera's products. In
addition, Lumiera is continuing to build online sales with
e-retailers such as Amazon and Lumiera's own Holizen.ca and
Awaye.ca websites.
"Following the launch of the new corporate strategy developed in
the first half of 2021, I'm very pleased to say that the growth we
began to experience in Q3'21 led to record sales in Q4'21, and
another strong quarter in Q1'22. Based on our success, we are
increasing our investment in inventory to enable us to capitalize
on additional growth opportunities. From a profitability
perspective, we are particularly excited by the fact that our
growth is also leading to increased margins," says Carlos Ponce, CEO of Lumiera. "Moving
forward, we are laser focused on increasing our retail and online
distribution; based on the positive feedback we have from people
that have tried our Bazzzics sleep aids and Awaye pain relief
cream, we know that distribution expansion leads to accelerated
sales growth and we expect revenues to increase exponentially."
Management will continue executing its plan for growth and
expects to see the upward sales trends continue for the foreseeable
future.
Audited financial statements will be released on or before
March 31, 2022.
About Lumiera
Health
Lumiera specializes in the development and commercialization of
consumer products for the natural health industry. The Company
sells herbal tonics and natural supplements through its Holizen
Laboratories division, with a diverse portfolio including a line of
innovative sleep aids. The Company is also developing and
commercializing a unique range of products acting on the
endocannabinoid system and offering novel solutions for the
treatment of acute and chronic pain. A pioneer in the natural
health innovation space, the Lumiera brand is rooted in the core
values of science, nature and compassion. Our goal is to make
people's lives better by developing natural health and wellness
products that are effective, safe and trustworthy.
For more information visit: www.lumiera.ca.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking
information
Certain statements contained in this press release constitute
"forward-looking information" as such term is defined in applicable
Canadian securities legislation. The words "may", "would", "could",
"should", "potential", "will", "seek", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar
expressions indicate such "forward-looking
information" as they relate to Lumiera. All statements other
than statements of historical fact may be forward-looking
information. Such statements reflect Lumiera' current views and
intentions with respect to future events, and current information
available to Lumiera, and are subject to certain risks,
uncertainties and assumptions. Such risks and uncertainties
include, among others, the risk factors included in Lumiera' annual
management's discussion and analysis for the year
ended November 30, 2020,
which is available under the issuer's SEDAR profile
at www.sedar.com. Material factors or assumptions
were applied in providing forward-looking information. Many factors
could cause the actual results, performance or achievements that
may be expressed or implied by such forward-looking information to
vary from those described herein should one or more of these risks
or uncertainties materialize. Should any factor affect Lumiera in
an unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, Lumiera does not
assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and Lumiera undertakes no obligation to publicly update or
revise any forward-looking information, other than as required by
applicable law.
SOURCE Lumiera Health Inc.